Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Toyota Global Sales Fall as China Demand Slumps 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Street Poller Media and The Boom of the Street Interview Ad Industry 
(4) - EconoTimes)
Add as a preferred source on Google
BOSTON, April 03, 2018 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant to five employees of inducement stock options exercisable for an aggregate of 80,000 shares of Albireo’s common stock. The stock options are exercisable at a price of $32.57 per share, the closing price of Albireo’s common stock on March 29, 2018, the grant date, and were granted as inducements material to each employee’s acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has a 10-year term and vests over a four-year period, subject to the employee’s continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee’s start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo’s 2017 Inducement Equity Incentive Plan.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Sarah Hall
6 Degrees
215-313-5638
[email protected]
Source: Albireo Pharma, Inc.
